How Bacteria Eat Penicillin

Scientists work out the specific genes and biochemical steps required for digesting the very drugs designed to kill microbes.

Apr 30, 2018
Shawna Williams

Researchers synthesized some penicillin breakdown products themselves for use in the experiments.TERENCE CROFTSome bacteria take antibiotic resistance a step further: they chow down on the very compounds designed to kill microbes and use them as fuel. Researchers detail today (April 30) in Nature Chemical Biology how some bacteria accomplish this feat, including the genes and enzymes involved in digesting penicillin. They hope the knowledge will eventually be put to work in applications such as breaking down antibiotics in, for example, hospital waste or farm runoff, and constructing novel drug compounds.

“Basically, if you look for it it’s there in when it comes to bacterial degradation of compounds. . . . Somebody out there will degrade just about everything,” says Jo Handelsman, a microbiologist at the University of Wisconsin-Madison. “I don’t think that penicillin-producing strains of Penicillium are absolutely ubiquitous in soil, so it is kind of interesting that it is easy to find these degraders, even though they may not individually have encountered penicillin before.”

Guatam Dantas, a microbiologist at Washington University in St. Louis, stumbled across the phenomenon of antibiotic-eating bacteria during an earlier study looking for bacteria that can break down toxins, he explains. In that study, his group chose some antibiotics as controls to measure microbes’ responses to compounds they couldn’t eat—or so the researchers thought.

Instead, Dantas was surprised to find that some of the bacteria could, in fact, eat the drugs, and he began asking colleagues to send him soil samples from different places so his team could test for the presence of such microbes. As it turned out, they were everywhere. He also found examples of the phenomenon in the scientific literature going back to the 1960s.

“What has been missing has been any kind of mechanistic elucidation of how this occurs,” he says. So his team set out to deconstruct the steps needed to break down penicillin—selected because it and its derivatives are the largest class of antibiotics—into microbial fuel.

The project ended up taking about a decade, Dantas tells The Scientist, largely because the penicillin-eating microbes aren’t model organisms, and the team had to develop or adapt techniques to knock out certain genes and otherwise manipulate them.

As part of their experiments, the researchers exposed the microbes to one type of partially broken-down penicillin compound at a time to determine the order of steps in the degradation pathway. To do so, they first had to synthesize some of the compounds themselves. Once the researchers thought they’d figured out all the genes involved in the pathway, they transfected them into E. coli and gave them the ability to eat penicillin.

Dantas suggests that, similarly, the genes could be used to specially engineer microbes to break down antibiotic pollutants—for example, in waste from farms where the drugs have been used in livestock or in effluent from hospitals.

The idea of engineering antibiotic-eating bacteria to combat the spread of drug resistance is counterintuitive, but Dantas is cognizant of safety concerns. The gene used in the first step of the pathway, which codes for an enzyme that deactivates penicillin, is the same one already used by penicillin-resistant pathogens, so, he argues, such an approach wouldn’t be introducing new resistance genes to the environment—though he concedes that “you never want to play around with any kind of genetic engineering without very carefully thinking of the risk and what the mitigation strategies might be.” A lower-risk alternative, he says, might be to deploy the bacterial enzymes but not bacteria themselves.

An experiment to detect cleavage of a penicillin product by bacterial enzymesTERENCE CROFTThe idea is “very ambitious,” but such a system would likely be too expensive to make significant headway on cleaning up antibiotics in the environment, says Julian Davies, a microbiologist at the University of British Columbia in Vancouver who was not involved in the study.

Microbiologist Xiaohui Zhou of the University of Connecticut sees promise in putting the enzymes to work making new antibiotics, because they cut existing compounds in predictable places, and the resulting pieces could be mixed and matched to create semi-synthetic drugs.

Now that the methodologies to identify these enzymes and their pathways have been worked out, Dantas says he expects other researchers will be able to begin discovering enzymes and pathways microbes use to break down other types of antibiotics, further adding to the biotechnological tools chemists and biochemists have at their disposal.

T.S. Crofts, “Shared strategies for β-lactam catabolism in the soil microbiome,” Nat Chem Biol, doi:10.1038/s41589-018-0052, 2018.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!